NASDAQ:JNCEJounce Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jounce Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.56 +0.17 (+3.15 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$5.28Now: $5.56▼$5.6850-Day Range$4.53MA: $5.02▼$5.6852-Week Range$2.79Now: $5.56▼$10.00Volume233,900 shsAverage Volume372,056 shsMarket Capitalization$189.33 millionP/E Ratio4.52Dividend YieldN/ABeta2.37 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. It is also developing JTX-4014, a monoclonal antibody that is in Phase I clinical trial for combination therapy; and JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2 that is in the IND-enabling phase. The company has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingJounce Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Jounce Therapeutics has a potential upside of 70.9% from its current price of $5.56.Amount of Analyst CoverageJounce Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesJounce Therapeutics has received 253 “outperform” votes. (Add your “outperform” vote.)Underperform VotesJounce Therapeutics has received 222 “underperform” votes. (Add your “underperform” vote.)Community SentimentJounce Therapeutics has received 53.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote “Outperform” if you believe JNCE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldJounce Therapeutics does not currently pay a dividend.Dividend GrowthJounce Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jounce Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders44.41% of the stock of Jounce Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.76% of the stock of Jounce Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Jounce Therapeutics are expected to grow in the coming year, from ($2.39) to ($2.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jounce Therapeutics is 4.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 15.72.Price to Earnings Ratio vs. SectorThe P/E ratio of Jounce Therapeutics is 4.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.49.Price to Book Value per Share RatioJounce Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.97 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JNCE Previous Symbol CUSIPN/A CIK1640455 Webwww.jouncetx.com Phone857-259-3840Debt Debt-to-Equity Ratio0.11 Current Ratio10.66 Quick Ratio10.66Price-To-Earnings Trailing P/E Ratio4.52 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$147.87 million Price / Sales1.28 Cash Flow$1.83 per share Price / Cash Flow3.03 Book Value$5.25 per share Price / Book1.06Profitability EPS (Most Recent Fiscal Year)$1.66 Net Income$56.82 million Net Margins46.11% Return on Equity28.10% Return on Assets21.33%Miscellaneous Employees115 Outstanding Shares34,053,000Market Cap$189.33 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:JNCE Rates by TradingView Receive JNCE News and Ratings via Email Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter. Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions How has Jounce Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, JNCE stock has increased by 29.9% and is now trading at $5.56. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Jounce Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating, 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jounce Therapeutics. When is Jounce Therapeutics' next earnings date? Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Jounce Therapeutics. How were Jounce Therapeutics' earnings last quarter? Jounce Therapeutics Inc (NASDAQ:JNCE) issued its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.21. Jounce Therapeutics had a net margin of 46.11% and a return on equity of 28.10%. View Jounce Therapeutics' earnings history. What price target have analysts set for JNCE? 4 brokerages have issued 1 year price targets for Jounce Therapeutics' stock. Their forecasts range from $8.00 to $11.00. On average, they expect Jounce Therapeutics' stock price to reach $9.50 in the next year. This suggests a possible upside of 70.9% from the stock's current price. View analysts' price targets for Jounce Therapeutics. Has Jounce Therapeutics been receiving favorable news coverage? Media headlines about JNCE stock have been trending very negative recently, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Jounce Therapeutics earned a coverage optimism score of -3.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutJounce Therapeutics. Are investors shorting Jounce Therapeutics? Jounce Therapeutics saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 2,000,000 shares, a drop of 11.9% from the April 15th total of 2,270,000 shares. Based on an average daily volume of 378,700 shares, the short-interest ratio is currently 5.3 days. Currently, 12.3% of the company's stock are short sold. View Jounce Therapeutics' Current Options Chain. Who are some of Jounce Therapeutics' key competitors? Some companies that are related to Jounce Therapeutics include AVITA MED LTD/S (RCEL), Agenus (AGEN), BioCryst Pharmaceuticals (BCRX), Replimune Group (REPL), Aerie Pharmaceuticals (AERI), Aptose Biosciences (APTO), Nantkwest (NK), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Vericel (VCEL), Atara Biotherapeutics (ATRA), Oyster Point Pharma (OYST), Prevail Therapeutics (PRVL), MeiraGTx (MGTX) and Scholar Rock (SRRK). View all competitors. What other stocks do shareholders of Jounce Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), Crispr Therapeutics (CRSP), Progenics Pharmaceuticals (PGNX), Bausch Health Companies (BHC), Exelixis (EXEL), Incyte (INCY), Nektar Therapeutics (NKTR), Omeros (OMER), Sangamo Therapeutics (SGMO) and AT&T (T). Who are Jounce Therapeutics' key executives? Jounce Therapeutics' management team includes the following people: Dr. Richard Murray, Pres, CEO & Director (Age 60)Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 54)Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 59)Dr. James P. Allison, FounderDr. Thomas F. Gajewski, Founder When did Jounce Therapeutics IPO? (JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers. What is Jounce Therapeutics' stock symbol? Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE." Who are Jounce Therapeutics' major shareholders? Jounce Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.65%), Acadian Asset Management LLC (2.81%), AQR Capital Management LLC (1.83%), State Street Corp (1.23%), Massachusetts Financial Services Co. MA (0.83%) and Granahan Investment Management Inc. MA (0.78%). Company insiders that own Jounce Therapeutics stock include Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View institutional ownership trends for Jounce Therapeutics. Which major investors are selling Jounce Therapeutics stock? JNCE stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Deutsche Bank AG, JPMorgan Chase & Co., Geode Capital Management LLC, Bank of New York Mellon Corp, Systematic Financial Management LP, UBS Group AG, and Morgan Stanley. Company insiders that have sold Jounce Therapeutics company stock in the last year include Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, and Richard /Ca/ Murray. View insider buying and selling activity for Jounce Therapeutics. Which major investors are buying Jounce Therapeutics stock? JNCE stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Massachusetts Financial Services Co. MA, Acadian Asset Management LLC, Russell Investments Group Ltd., Granahan Investment Management Inc. MA, Congress Asset Management Co. MA, Los Angeles Capital Management & Equity Research Inc., and GSA Capital Partners LLP. View insider buying and selling activity for Jounce Therapeutics. How do I buy shares of Jounce Therapeutics? Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Jounce Therapeutics' stock price today? One share of JNCE stock can currently be purchased for approximately $5.56. How big of a company is Jounce Therapeutics? Jounce Therapeutics has a market capitalization of $189.33 million and generates $147.87 million in revenue each year. The company earns $56.82 million in net income (profit) each year or $1.66 on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe. What is Jounce Therapeutics' official website? The official website for Jounce Therapeutics is www.jouncetx.com. How can I contact Jounce Therapeutics? Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840. This page was last updated on 6/2/2020 by MarketBeat.com Staff
